Speaker Profile
M.D., Chief, Early Phase Drug Development, Sarah Cannon
Biography
Vivek Subbiah, MD, joined Sarah Cannon Research Institute (SCRI) in 2023, and serves as chief, Early-Phase Drug Development. In his role, Dr. Subbiah oversees SCRI's nine drug development units and leads the expansion of early-phase capabilities and programs across SCRI's growing research network. Dr. Vivek Subbiah comes to SCRI from the University of Texas MD Anderson Cancer Center where he was an associate professor in the Department of Investigational Cancer Therapeutics. During his near 15-year tenure there, Dr. Vivek Subbiah held several leadership roles including Executive Director, Medical Oncology Research, MD Anderson Cancer Network as well as Clinical Medical Director, Division of Cancer Medicine where he oversaw both the outpatient and inpatient clinical care delivery operations for the Phase I program. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase III trials and co-investigator in over 200 clinical trials.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Razelle Kurzrock, Emory
PMWC Award Ceremony
• Antoni Ribas, UCLA Health (Luminary)
Featured Speakers
• Antoni Ribas, UCLA Health
• Gerold Meinhardt, Daiichi Sankyo
• Katy Rezvani, MD Anderson
• Javad Shahidi, BeOne
• Alicia Zhou, Cancer Research Institute
• Oren Gilad, Aprea Therapeutics
• Adam Palmer, UNC
• Trever Bivona, UCSF
• Laura Volta, Penn Medicine
• Vivek Subbiah, Stanford
• Mark Stewart, Friends of Cancer Research
Precision Immunotherapy After PD-1
Cells, bispecifics, ADCs, and new combination logic after checkpoint failure.
Biomarkers That Matter
Selecting patients for immunotherapy and targeted therapy with decision-grade biomarkers.
Resistance Biology & Adaptive Combination Strategies
How tumors adapt, and how to sequence therapy around that biology.
Which Immune Cells Can Be Programmed In Vivo?
The next wave of immune-cell engineering and where it may matter first.
Rare Cancers, Basket Trials & N-of-1 Playbooks
Moving from histology-agnostic evidence to individualized precision oncology.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
